171 related articles for article (PubMed ID: 28154086)
1. Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia.
Chevallier P; Chantepie S; Huguet F; Raffoux E; Thomas X; Leguay T; Marchand T; Isnard F; Charbonnier A; Maury S; Gallego-Hernanz MP; Robillard N; Guillaume T; Peterlin P; Garnier A; Rialland F; Le Houerou C; Goldenberg DM; Wegener WA; Béné MC; Dombret H
Haematologica; 2017 May; 102(5):e184-e186. PubMed ID: 28154086
[No Abstract] [Full Text] [Related]
2. Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study.
Chevallier P; Huguet F; Raffoux E; Etienne A; Leguay T; Isnard F; Robillard N; Guillaume T; Delaunay J; Charbonnier A; Pigneux A; Peterlin P; Bené MC; Wegener WA; Goldenberg DM; Dombret H
Haematologica; 2015 Apr; 100(4):e128-31. PubMed ID: 25552705
[No Abstract] [Full Text] [Related]
3. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.
Weiser MA; Cabanillas ME; Konopleva M; Thomas DA; Pierce SA; Escalante CP; Kantarjian HM; O'Brien SM
Cancer; 2004 Mar; 100(6):1179-85. PubMed ID: 15022284
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
Kantarjian H; Thomas D; O'Brien S; Cortes J; Giles F; Jeha S; Bueso-Ramos CE; Pierce S; Shan J; Koller C; Beran M; Keating M; Freireich EJ
Cancer; 2004 Dec; 101(12):2788-801. PubMed ID: 15481055
[TBL] [Abstract][Full Text] [Related]
5. Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial.
Jabbour E; Ravandi F; Kebriaei P; Huang X; Short NJ; Thomas D; Sasaki K; Rytting M; Jain N; Konopleva M; Garcia-Manero G; Champlin R; Marin D; Kadia T; Cortes J; Estrov Z; Takahashi K; Patel Y; Khouri MR; Jacob J; Garris R; O'Brien S; Kantarjian H
JAMA Oncol; 2018 Feb; 4(2):230-234. PubMed ID: 28859185
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) compared to Hyper-CVAD regimen as salvage chemotherapy in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
Liu L; Jiao W; Zhang Y; Qu Q; Li X; Wu D
Leuk Res; 2015 Mar; 39(3):323-8. PubMed ID: 25638269
[TBL] [Abstract][Full Text] [Related]
7. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Daver N; Thomas D; Ravandi F; Cortes J; Garris R; Jabbour E; Garcia-Manero G; Borthakur G; Kadia T; Rytting M; Konopleva M; Kantarjian H; O'Brien S
Haematologica; 2015 May; 100(5):653-61. PubMed ID: 25682595
[TBL] [Abstract][Full Text] [Related]
8. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma.
Thomas DA; O'Brien S; Cortes J; Giles FJ; Faderl S; Verstovsek S; Ferrajoli A; Koller C; Beran M; Pierce S; Ha CS; Cabanillas F; Keating MJ; Kantarjian H
Blood; 2004 Sep; 104(6):1624-30. PubMed ID: 15178574
[TBL] [Abstract][Full Text] [Related]
9. Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen.
Weiser MA; O'Brien S; Thomas DA; Pierce SA; Lam TP; Kantarjian HM
Cancer; 2002 Jan; 94(2):285-91. PubMed ID: 11900213
[TBL] [Abstract][Full Text] [Related]
10. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia.
Advani AS; McDonough S; Coutre S; Wood B; Radich J; Mims M; O'Donnell M; Elkins S; Becker M; Othus M; Appelbaum FR
Br J Haematol; 2014 May; 165(4):504-9. PubMed ID: 24579885
[TBL] [Abstract][Full Text] [Related]
11. Comparison between Hyper-CVAD and PETHEMA ALL-93 in Adult Acute Lymphoblastic Leukemia: A Single-Center Study.
Erkut N; Akidan O; Selim Batur D; Karabacak V; Sonmez M
Chemotherapy; 2018; 63(4):207-213. PubMed ID: 30304722
[TBL] [Abstract][Full Text] [Related]
12. [A clinical report on modified Hyper-CVAD regimen in patients with lymphoblastic lymphoma].
Shi W; Shi YK; He XH; Zhou SY; Dong M; Zhang CG; Yang JL; Liu P; Qin Y; Yang S; Gui L
Zhonghua Yi Xue Za Zhi; 2010 Apr; 90(14):978-81. PubMed ID: 20646648
[TBL] [Abstract][Full Text] [Related]
13. The Dana Farber consortium protocol (DFCP) vs. classic Hyper-CVAD for treatment of acute lymphoblastic leukemia in patients <50 Y. Single institution experience.
Alabdulwahab AS; Elsayed HG; Sherisher MA; Zeeneldin A; Alghamdi K; Elbjeirami WM
Leuk Res; 2017 Sep; 60():58-62. PubMed ID: 28704720
[TBL] [Abstract][Full Text] [Related]
14. Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia.
Thota S; Advani A
Eur J Haematol; 2017 May; 98(5):425-434. PubMed ID: 28152223
[TBL] [Abstract][Full Text] [Related]
15. Feasibility and outcome of the hyper-CVAD regimen in patients with adult acute lymphoblastic leukemia.
Portugal RD; Loureiro MM; Garnica M; Pulcheri W; Nucci M
Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):52-7. PubMed ID: 25037887
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of the Hyper-CVAD with an institutional regimen for the treatment of acute lymphoblastic leukemia in adults in a hospital of Mexico].
Ramos-Peñafiel CO; Cabrera-García Á; Rozen-Fuller E; González-León G; Balderas C; Kassack-Ipiña JJ; Castellanos-Sinco H; Martínez-Murillo C; Montaño-Figueroa E; Martínez-Tovar A; Olarte-Carrillo I; Santoyo-Sánchez A; Collazo-Jaloma J
Rev Peru Med Exp Salud Publica; 2014; 31(3):525-9. PubMed ID: 25418653
[TBL] [Abstract][Full Text] [Related]
17. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.
Kantarjian HM; O'Brien S; Smith TL; Cortes J; Giles FJ; Beran M; Pierce S; Huh Y; Andreeff M; Koller C; Ha CS; Keating MJ; Murphy S; Freireich EJ
J Clin Oncol; 2000 Feb; 18(3):547-61. PubMed ID: 10653870
[TBL] [Abstract][Full Text] [Related]
18. Daratumumab for quick and sustained remission in post-transplant relapsed/refractory acute lymphoblastic leukemia.
Zhang Y; Xue S; Liu F; Wang J
Leuk Res; 2020 Apr; 91():106332. PubMed ID: 32126433
[No Abstract] [Full Text] [Related]
19. Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia.
Bertamini L; Nanni J; Marconi G; Abbenante M; Robustelli V; Bacci F; Matti A; Paolini S; Sartor C; Monaco SL; Fontana MC; De Polo S; Cavo M; Curti A; Martinelli G; Papayannidis C
BMC Cancer; 2018 Nov; 18(1):1117. PubMed ID: 30442119
[TBL] [Abstract][Full Text] [Related]
20. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.
Thomas DA; O'Brien S; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Ravandi F; Verstovsek S; Jorgensen JL; Bueso-Ramos C; Andreeff M; Pierce S; Garris R; Keating MJ; Cortes J; Kantarjian HM
J Clin Oncol; 2010 Aug; 28(24):3880-9. PubMed ID: 20660823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
